NCT04285749 is a EARLY_PHASE1 clinical trial of Fluvastatin in Malignant Melanoma, sponsored by Case Comprehensive Cancer Center.

Who is sponsoring NCT04285749?

NCT04285749 is sponsored by Case Comprehensive Cancer Center.

What drugs are being tested in NCT04285749?

Interventions in NCT04285749: Fluvastatin, RNA-sequencing, Gene expression profiling.

What condition does NCT04285749 study?

NCT04285749 studies Malignant Melanoma.

Is NCT04285749 still recruiting?

NCT04285749 is currently withdrawn. Last updated 27 July 2020.

Last reviewed 2020-07-27 · How we verify

NCT04285749

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Withdrawn EARLY_PHASE1 Last updated 27 July 2020

What this trial tests

EARLY_PHASE1 trial testing Fluvastatin in Malignant Melanoma. Withdrawn.

Timeline

6 November 2020

Primary endpoint
1 April 2021

1 April 2021

Quick facts

Lead sponsor	Case Comprehensive Cancer Center
Phase	EARLY_PHASE1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	6 November 2020
Primary completion	1 April 2021
Estimated completion	1 April 2021

Drugs / interventions tested

Fluvastatin (FLUVASTATIN) — full drug profile →
RNA-sequencing
Gene expression profiling

Conditions studied

Malignant Melanoma — all drugs for Malignant Melanoma →

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

Adults 18 to 99, any sex, with Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether a medication, fluvastatin, can change melanoma to a state that is less likely to metastasize or recur. Fluvastatin is experimental in this setting because it is not approved by the Food and Drug Administration (FDA) for treatment or prevention of melanoma. However, fluvastatin has been approved by the FDA for treating high cholesterol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fluvastatin

Trials testing the same drug.

NCT03510715 — An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia · Phase 3 · completed
NCT03510884 — An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia · Phase 3 · completed
NCT03189511 — Effect of Fluvastatin on Brown Fat Activity · Phase 4 · completed

Other recruiting trials for Malignant Melanoma

Currently open trials in the same condition.

NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06961006 — A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0 · Phase 2 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04285749 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
Last refreshed: 27 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04285749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing